Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT03532061 Completed - Cancer Clinical Trials

Caregivers' Strengths-Skills: Managing Older Cancer Patients' Symptoms

FamCare
Start date: August 7, 2006
Phase: N/A
Study type: Interventional

Caregiver education and training programs that specifically target caregiver informational and training needs during the survivorship period have been limited. In recognition of families' direct involvement in health care decision-making, health advocacy and care provision, programs are needed that can maximize families' caregiving abilities and skills and provide them with the information and resources they may need to identify and address elderly cancer patients' post-treatment symptom management. The goal of this study was to implement and evaluate the efficacy of a short-term problem-solving skills training program (relative to participating in a caregiver support group) for familial caregivers to lower income older (55+) post-treatment cancer patients.

NCT ID: NCT03530215 Completed - Cancer Clinical Trials

Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)

EROCA
Start date: May 2, 2018
Phase:
Study type: Observational

Antineoplastic and immunomodulating agents may lead to various cardio-vascular adverse reactions. This study investigates reports of cardio-vascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC) classification L (antineoplastic agents, endocrine therapy, immunostimulants, and immunosuppressants drugs) in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).

NCT ID: NCT03527225 Completed - Cancer Clinical Trials

Music of Choice to Decrease Anxiety During Radiation Treatment

Start date: January 22, 2018
Phase: N/A
Study type: Interventional

The primary hypothesis of the study is that listening to music will reduce anxiety in female cancer patients during the first radiotherapy treatment session.

NCT ID: NCT03525236 Completed - Cancer Clinical Trials

The Oncoflavour Study

Start date: June 19, 2017
Phase: N/A
Study type: Interventional

Oral nutritional supplements (ONS) are often prescribed for malnourished patients to help improve nutritional status. Commonly in cancer patients taste and smell alterations and side effects of treatment can affect the palatability and compliance to ONS. A variety of flavours and styles are available of ONS however research of the palatability of these in cancer patients is limited. This study aims to evaluate specific flavours created based on the taste changes occuring during treatment. We aim to evaluate the patient liking and evaluation of 5 flavors in 3 different types of flavour-sensations: - Warming/spicy sensation: to trigger the senses and bring new sensations - Cooling/fresh sensation: to have a fresh mouthfeel and lighter base perception - Neutral: to avoid that patients experience additional flavour and let them the opportunity to mix it with other food

NCT ID: NCT03518255 Completed - Cancer Clinical Trials

e-Natureza Project - Affective Validation of Nature Images for Hospital Use

E-natureza
Start date: August 22, 2018
Phase: N/A
Study type: Interventional

Randomized clinical trial about the evaluation of the use of nature photographs in the positive and negative affects of oncological patients.

NCT ID: NCT03514680 Completed - Cancer Clinical Trials

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

Start date: June 4, 2018
Phase: N/A
Study type: Interventional

This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.

NCT ID: NCT03512899 Completed - Cancer Clinical Trials

Comparison Between Internal Jugular Vein Versus Axillary Vein for Implantable Ports

Start date: April 1, 2017
Phase: N/A
Study type: Interventional

Comparison between internal jugular vein versus via axillary vein with single-incision for placement of implantable ports in cancer patients. Investigators are recruiting 240 patients and randomizing 120 for each arm. Primary outcome is early complications, until 30 days and secondary outcome late complications, between 30 days and 6 months. The follow-up is 12 months.

NCT ID: NCT03506815 Completed - Cancer Clinical Trials

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

TRIM-Line
Start date: March 15, 2019
Phase: Phase 3
Study type: Interventional

Purpose of Pilot Trial To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated venous thromboembolism(VTE) among cancer patients. Hypothesis: treatment with low dose rivaroxaban (10mg) will reduce the incidence of upper extremity venous thrombosis in a high risk population with cancer and CVC. Design: This is a pilot interventional study to be conducted at 3 Canadian Centres. The Ottawa Hospital, QEII Health Science Centre and University of Alberta Hospital. It is an open label randomized controlled trial. Consenting participants, meeting eligibility criteria will be randomized at the time of enrollment to one of two groups. Rivaroxaban 10mg po daily x 90 (+/- 3 ) days OR Standard of Care Participants in the treatment arm will have study drug dispensed at Day 1 and take medication for 90 days. Follow up visits (in person or phone) will occur at Day 30 (+/- 3 days) and Day 90 (+/- 3 days) month and 3 months post enrollment. Overall, participants will be followed for 3 months. Adverse events will be collected for the first 90 days. Outcomes The primary feasibility outcome for the pilot study is the number of participants recruited per centre per month. We will obtain baseline details of the patient's type, location and treatment of cancer, comorbidities and medications. Secondary feasibility outcomes of the pilot study will include, consent rates, loss to follow up, adherence to therapy defining 80% or greater medication taken as having good adherence to study drug, proportion of screened patients who meet eligibility criteria.

NCT ID: NCT03503838 Completed - Cancer Clinical Trials

A Pilot Study of Online Yoga for MPN Patients

Start date: September 23, 2016
Phase: N/A
Study type: Interventional

Polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis (MF) are chronic Philadelphia negative myeloproliferative neoplasms (MPNs) that are characterized by clonal proliferation of hematopoietic stem cells, intramedullary fibrosis, and splenomegaly. While disease manifestations may vary amongst the spectrum of MPNs, quality of life considerations including fatigue, concentration difficulties, pain, sleep disturbance, and depression are negatively affected in most MPN patients. Inflammation has been suggested to be involved in the development of disease-related symptoms. Specific pro-inflammatory cytokines (e.g., IL-1, IL-6, IL-8, and TNF-α) have been associated with particular patient-reported symptoms, including fatigue, abdominal complaints, microvascular symptoms, and constitutional symptoms. Pharmacologic therapy can positively impact MPN related symptoms, specifically with JAK inhibition, however, these treatments often come with negative side effects (e.g., anemia, thrombocytopenia). Much opportunity remains for improving MPN symptoms (i.e., fatigue, insomnia, loss of muscle mass, and debilitation) and quality of life. Yoga, a gentle form of meditative exercise, has been shown to improve symptom management and quality of life parameters in cancer patients and may be effective in improving MPN-related symptoms. Here we propose a study evaluating the efficacy of an online yoga intervention comparing a yoga group to a wait-list control group for improving symptom burden and quality of life in MPN patients. Secondarily, we plan to evaluate the feasibility of collecting potential biomarkers that are related to MPN disease-related activity, such as fatigue (i.e., cortisol and serum cytokines).

NCT ID: NCT03495323 Completed - Cancer Clinical Trials

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Start date: May 16, 2018
Phase: Phase 1
Study type: Interventional

This research study is studying a combination of a targeted therapy and an immune therapy as a possible treatment. The drugs involved in this study are: - Prexasertib (LY2606368) - LY3300054